WAGNER CHARLES F JR
SEC CIK 1223348 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | EVP, CO, FO | 47.0K | — | $24.04M | 41 | 2022-02-01 | 2026-02-24 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 41
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | F - Tax | $485.11 | -1,744 | 47.0K | -4% | -$846.0K | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | A - Grant | $0.00 | +7,365 | 51.1K | +17% | $0 | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | F - Tax | $483.75 | -2,294 | 48.8K | -4% | -$1.11M | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | F - Tax | $487.76 | -4,565 | 43.7K | -9% | -$2.23M | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | F - Tax | $468.41 | -3,045 | 48.3K | -6% | -$1.43M | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | A - Grant | $0.00 | +13.6K | 51.3K | +36% | $0 |
| D | 2026-01-08 | 2026-01-06 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | M - OptEx | $189.38 | +9,532 | 47.3K | +25% | +$1.81M |
| D | 2026-01-08 | 2026-01-06 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | S - Sale+OE | $461.00 | -9,532 | 37.7K | -20% | -$4.39M |
| M | 2025-12-05 | 2025-12-03 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CO, FO | S - Sale | $456.00 | -14.0K | 37.7K | -27% | -$6.38M |
| 2025-03-12 | 2025-03-10 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $500.00 | -3,298 | 51.7K | -6% | -$1.65M | |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $479.61 | -4,962 | 55.0K | -8% | -$2.38M | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $483.28 | -3,310 | 59.9K | -5% | -$1.60M | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $463.46 | -2,293 | 63.2K | -3% | -$1.06M | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +6,655 | 65.5K | +11% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $467.98 | -2,649 | 58.9K | -4% | -$1.24M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +17.4K | 61.5K | +39% | $0 |
| 2024-11-13 | 2024-11-11 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $518.27 | -3,000 | 44.1K | -6% | -$1.55M | |
| 2024-06-05 | 2024-06-03 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $460.00 | -3,250 | 47.1K | -6% | -$1.50M | |
| 2024-05-30 | 2024-05-28 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $454.79 | -3,250 | 50.4K | -6% | -$1.48M | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $431.79 | -3,309 | 53.6K | -6% | -$1.43M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $422.54 | -6,562 | 56.9K | -10% | -$2.77M |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $422.74 | -2,607 | 63.5K | -4% | -$1.10M | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +22.4K | 58.9K | +61% | $0 |
| 2024-01-04 | 2024-01-02 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $405.00 | -3,000 | 43.7K | -6% | -$1.22M | |
| 2023-11-21 | 2023-11-20 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $349.88 | -3,000 | 46.7K | -6% | -$1.05M | |
| 2023-03-28 | 2023-03-24 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $305.38 | -1,768 | 49.6K | -3% | -$539.9K | |
| M | 2023-03-21 | 2023-03-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $296.39 | -2,000 | 51.6K | -4% | -$592.8K |
| M | 2023-03-14 | 2023-03-10+ | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $291.98 | -4,754 | 56.9K | -8% | -$1.39M |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $289.12 | -3,308 | 58.1K | -5% | -$956.4K | |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $292.85 | -3,750 | 61.4K | -6% | -$1.10M | |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $296.88 | -7,699 | 65.2K | -11% | -$2.29M |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +30.0K | 53.2K | +130% | $0 |
| M | 2022-05-04 | 2022-05-02 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $258.83 | -343 | 43.0K | -0.8% | -$88.8K |
| 2022-05-03 | 2022-04-29 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $276.17 | -547 | 43.1K | -1% | -$151.1K | |
| M | 2022-04-05 | 2022-04-01 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $264.76 | -2,582 | 43.8K | -6% | -$683.6K |
| M | 2022-03-21 | 2022-03-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $250.15 | -3,171 | 46.3K | -6% | -$793.2K |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $227.86 | -2,189 | 49.4K | -4% | -$498.8K | |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $232.51 | -3,439 | 51.6K | -6% | -$799.6K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $237.74 | -2,434 | 55.0K | -4% | -$578.7K | |
| 2022-02-03 | 2022-02-02 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $250.07 | -2,944 | 57.4K | -5% | -$736.2K | |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +25.6K | 50.1K | +104% | $0 |
Purchase Sale Sale after option exercise All abbreviations